Exogenous glucagon-like peptide-1 attenuates the glycaemic response to postpyloric nutrient infusion in critically ill patients with type-2 diabetes

Critical Care

Volumn 15, Issue 1, 2011, Pages

  Deane, Adam M ^a,b,c   Summers, Matthew J ^b   Zaknic, Antony V ^b   Chapman, Marianne J ^a,b,c   Fraser, Robert J L ^c,d,e   Di Bartolomeo, Anna E ^a   Wishart, Judith M ^d   Horowitz, Michael ^d  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b ROYAL ADELAIDE HOSPITAL   (Australia)

^c NATIONAL HEALTH AND MEDICAL RESEARCH COUNCIL   (Australia)

^d UNIVERSITY OF ADELAIDE   (Australia)

^e REPATRIATION GENERAL HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; PLACEBO; ANTIDIABETIC AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; ARTIFICIAL VENTILATION; CRITICALLY ILL PATIENT; ENTERIC FEEDING; FEMALE; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLYCEMIC INDEX; HUMAN; INSULIN BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SMALL INTESTINE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICAL ILLNESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; INTENSIVE CARE; METHODOLOGY; MIDDLE AGED; PYLORUS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

BLOOD GLUCOSE; CRITICAL CARE; CRITICAL ILLNESS; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENTERAL NUTRITION; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PYLORUS; TREATMENT OUTCOME;

EID: 78651548468     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc9983     Document Type: Article

References (32)

1. Finfer S, Chittock DR, Su SY, Blair D, Foster D, Dhingra V, Bellomo R, Cook D, Dodek P, Henderson WR, Hébert PC, Heritier S, Heyland DK, McArthur C, McDonald E, Mitchell I, Myburgh JA, Norton R, Potter J, Robinson BG, Ronco JJ. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009, 360:1283-1297. 10.1056/NEJMoa0810625, 19318384.
2. Egi M, Bellomo R, Stachowski E, French CJ, Hart GK, Hegarty C, Bailey M. Blood glucose concentration and outcome of critical illness: the impact of diabetes. Crit Care Med 2008, 36:2249-2255. 10.1097/CCM.0b013e318181039a, 18664780.
3. Marik PE, Raghavan M. Stress-hyperglycemia, insulin and immunomodulation in sepsis. Intensive Care Med 2004, 30:748-756. 10.1007/s00134-004-2167-y, 14991101.
4. Deacon CF. What do we know about the secretion and degradation of incretin hormones?. Regul Pept 2005, 128:117-124. 10.1016/j.regpep.2004.06.007, 15780431.
5. Nauck MA, Meier JJ. Glucagon-like peptide 1 and its derivatives in the treatment of diabetes. Regul Pept 2005, 128:135-148. 10.1016/j.regpep.2004.07.014, 15780433.
6. Nauck MA, Heimesaat MM, Behle K, Holst JJ, Nauck MS, Ritzel R, Hufner M, Schmiegel WH. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 2002, 87:1239-1246. 10.1210/jc.87.3.1239, 11889194.
7. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005, 143:559-569.
8. Deane AM, Chapman MJ, Fraser RJ, Burgstad CM, Besanko LK, Horowitz M. The effect of exogenous glucagon-like peptide-1 on the glycaemic response to small intestinal nutrient in the critically ill: a randomised double-blind placebo-controlled cross over study. Crit Care 2009, 13:R67. 10.1186/cc7874, 2717426, 19439067.
9. Deane AM, Chapman MJ, Fraser RJ, Summers MJ, Zaknic AV, Storey JP, Jones KL, Rayner CK, Horowitz M. Effects of exogenous glucagon-like peptide-1 on gastric emptying and glucose absorption in the critically ill: relationship to glycemia. Crit Care Med 2010, 38:1261-1269.
10. Deane AM, Fraser RJ, Young RJ, Foreman B, O'Conner SN, Chapman MJ. Evaluation of a bedside technique for postpyloric placement of feeding catheters. Crit Care Resusc 2009, 11:180-183.
11. Deane AM, Nguyen NQ, Stevens JE, Fraser RJ, Holloway RH, Besanko LK, Burgstad C, Jones KL, Chapman MJ, Rayner CK, Horowitz M. Endogenous glucagon-like peptide-1 slows gastric emptying in healthy subjects, attenuating postprandial glycemia. J Clin Endocrinol Metab 2010, 95:215-221. 10.1210/jc.2009-1503, 19892837.
12. Streiner DL. The case of the missing data: methods of dealing with dropouts and other research vagaries. Can J Psychiatry 2002, 47:68-75.
13. Nauck MA, Walberg J, Vethacke A, El-Ouaghlidi A, Senkal M, Holst JJ, Gallwitz B, Schmidt WE, Schmiegel W. Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1. Regul Pept 2004, 118:89-97. 10.1016/j.regpep.2003.11.003, 14759561.
14. Meier JJ, Weyhe D, Michaely M, Senkal M, Zumtobel V, Nauck MA, Holst JJ, Schmidt WE, Gallwitz B. Intravenous glucagon-like peptide 1 normalizes blood glucose after major surgery in patients with type 2 diabetes. Crit Care Med 2004, 32:848-851. 10.1097/01.CCM.0000114811.60629.B5, 15090972.
15. Larsen J, Hylleberg B, Ng K, Damsbo P. Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment. Diabetes Care 2001, 24:1416-1421. 10.2337/diacare.24.8.1416, 11473079.
16. Mussig K, Oncu A, Lindauer P, Heininger A, Aebert H, Unertl K, Ziemer G, Haring HU, Holst JJ, Gallwitz B. Effects of intravenous glucagon-like peptide-1 on glucose control and hemodynamics after coronary artery bypass surgery in patients with type 2 diabetes. Am J Cardiol 2008, 102:646-647. 10.1016/j.amjcard.2008.06.029, 18721530.
17. Mecott GA, Herndon DN, Kulp GA, Brooks NC, Al-Mousawi AM, Kraft R, Rivero HG, Williams FN, Branski LK, Jeschke MG. The use of exenatide in severely burned pediatric patients. Crit Care 2010, 14:R153. 10.1186/cc9222, 2945137, 20701787.
18. Willms B, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Nauck MA. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab 1996, 81:327-332. 10.1210/jc.81.1.327, 8550773.
19. Little TJ, Pilichiewicz AN, Russo A, Phillips L, Jones KL, Nauck MA, Wishart J, Horowitz M, Feinle-Bisset C. Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses. J Clin Endocrinol Metab 2006, 91:1916-1923. 10.1210/jc.2005-2220, 16492694.
20. Heyland DK, Tougas G, King D, Cook DJ. Impaired gastric emptying in mechanically ventilated, critically ill patients. Intensive Care Med 1996, 22:1339-1344. 10.1007/BF01709548, 8986483.
21. Pilichiewicz AN, Chaikomin R, Brennan IM, Wishart JM, Rayner CK, Jones KL, Smout AJ, Horowitz M, Feinle-Bisset C. Load-dependent effects of duodenal glucose on glycemia, gastrointestinal hormones, antropyloroduodenal motility, and energy intake in healthy men. Am J Physiol Endocrinol Metab 2007, 293:E743-753. 10.1152/ajpendo.00159.2007, 17609258.
22. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993, 36:741-744. 10.1007/BF00401145, 8405741.
23. Sathananthan A, Vella A. Personalized pharmacotherapy for Type 2 diabetes mellitus. Per Med 2009, 6:417-422. 10.2217/pme.09.3, 2753279, 20161033.
24. Deane A, Chapman MJ, Fraser RJ, Horowitz M. Bench-to-bedside review: The gut as an endocrine organ in the critically ill. Crit Care 2010, 14:228. 10.1186/cc9039, 20887636.
25. Schirra J, Houck P, Wank U, Arnold R, Goke B, Katschinski M. Effects of glucagon-like peptide-1(7-36)amide on antro-pyloro-duodenal motility in the interdigestive state and with duodenal lipid perfusion in humans. Gut 2000, 46:622-631. 10.1136/gut.46.5.622, 1727942, 10764704.
26. Creutzfeldt WO, Kleine N, Willms B, Orskov C, Holst JJ, Nauck MA. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients. Diabetes Care 1996, 19:580-586. 10.2337/diacare.19.6.580, 8725855.
27. Hare KJ, Knop FK, Asmar M, Madsbad S, Deacon CF, Holst JJ, Vilsboll T. Preserved inhibitory potency of GLP-1 on glucagon secretion in type 2 diabetes mellitus. J Clin Endocrinol Metab 2009, 94:4679-4687. 10.1210/jc.2009-0921, 19837930.
28. Schwart S, Kohl BA. Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010, 3:227-242.
29. Muller WA, Faloona GR, Aguilar-Parada E, Unger RH. Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion. N Engl J Med 1970, 283:109-115. 10.1056/NEJM197007162830301, 4912452.
30. Nauck MA, Wollschlager D, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Willms B. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia 1996, 39:1546-1553. 10.1007/s001250050613, 8960841.
31. Meier JJ, Gethmann A, Götze O, Gallwitz B, Holst JJ, Schmidt WE, Nauck MA. Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. Diabetologia 2006, 49:452-458. 10.1007/s00125-005-0126-y, 16447057.
32. Elahi D, Egan JM, Shannon RP, Meneilly GS, Khatri A, Habener JF, Andersen DK. GLP-1 (9-36) amide, cleavage product of GLP-1 (7-36) amide, is a glucoregulatory peptide. Obesity (Silver Spring) 2008, 16:1501-1509. 10.1038/oby.2008.229, 18421270.